MRKR

Marker Therapeutics, Inc. (NASDAQ:MRKR) is a clinical-stage immuno-oncology company founded in 1999 and headquartered in Houston, Texas. The company went public in 2002 and focuses on developing innovative T cell-based immunotherapies and peptide-based vaccines for treating blood cancers and solid tumors. As a biotechnology firm in the clinical development phase, Marker Therapeutics operates without approved commercial products, instead advancing multiple experimental cancer treatments through various stages of human clinical trials.